Amber Therapeutics announced on 10 June it closed one of the biggest series A financing rounds for medtech in Europe with $100m raised to advance its neuromodulation therapy to treat urinary incontinence.
The financing round was led by New Enterprise Associates (NEA) as part of a syndicate of new investors F-Prime Capital,...







